Shanghai Titan Scientific Co., Ltd. (688133.SH): The actual controller has renewed the concerted action agreement.

Gelonghui reported on December 27 that Shanghai Titan Scientific Co.,Ltd. (688133.SH) announced that it has received notification from its actual controllers, Mr. Xie Yingbo, Mr. Zhang Qing, Mr. Zhang Hua, Mr. Xu Fengyuan, Mr. Wang Jingyu, and Ms. Zhang Weiyan regarding the renewal of the "Consistent Action Agreement." In view of the impending expiration of the "Consistent Action Agreement" signed by all parties on December 28, 2017 (referred to as the "original Consistent Action Agreement"), to improve corporate governance, ensure the continuity and stability of the company's operations, and achieve substantive and effective control of the company, all parties have renewed the "Consistent Action Agreement."

Gelonghui FinanceDec 27, 2024 16:56

shanghai titan scientific co.,ltd. (688133) Review of the third quarter report in 2024: Performance under pressure, waiting for a turnaround.

Item: In the first three quarters of 2024, the company achieved revenue of 2.126 billion yuan, a year-on-year increase of 3.49%; achieved net income attributable to the parent company of 0.01 billion yuan, a year-on-year decrease of 86.49%, with basic EPS of 0.06 yuan.

Huachuang SecuritiesNov 19, 2024 07:27

shanghai titan scientific co.,ltd. (688133): Entering a transformative period of improving profitability.

For companies in the scientific service sector, product capabilities, service capabilities, and production capabilities are all of great importance in development. shanghai titan scientific co.,ltd., as a rare full-process scientific service platform in the industry, has gradually passed the stage of strategic scale enhancement, and will further advance.

zheshang SecuritiesNov 8, 2024 20:07

Zheshang: Innovative drugs, blood products and other fields may benefit from the slow recovery on the demand side.

Zheshang released research reports stating that the transition of pharmaceutical new and old kinetic energy will continue in the next stage, with innovative drugs, supply cleaning or better framework in areas such as innovative drug supporting industry chain, large infusion, anesthetic drugs, blood products, pharmaceutical circulation, traditional chinese medicine OTC, benefiting from the slow recovery on the demand side, potentially with better growth prospects.

Zhitong FinanceNov 6, 2024 06:40

shanghai titan scientific co.,ltd. (688133.SH): tianjin Chuangfeng and its concerted action persons hold a total shareholding of less than 5%.

shanghai titan scientific co.,ltd. (688133.SH) announced that the company recently received a notice from tianjin chuangfeng and its concerted action person: Ning...

Zhitong FinanceNov 4, 2024 17:49

Titan Technology: Titan Tech Third Quarter 2024 Report

SZSIOct 31, 2024 00:00 · Announcements